

## 如何设置基于检索式的跟踪服务

以一个药物报告为例

欲检索符合以下条件的药物：

作用机制（Action）—EGFR 家族酪氨酸激酶受体抑制剂（EGFR family tyrosine kinase receptor inhibitor）

治疗领域（Therapy area）—肺部肿瘤（lung tumor）

国家（Country）—在美国和日本的进展（US OR Japan）

**步骤 1**

在 Form Search – Drugs 输入您的检索条件

例

Action:  
“EGFR family tyrosine kinase receptor inhibitor”

Therapy area: “Lung tumor”

Country: US OR Japan

**步骤 2**

检索条件设定完毕后，  
点击保存按钮

弹出一个窗口“SAVE FORM SEARCH – DRUGS”，提示您已保存“表格检索—药物”

**SAVE FORM SEARCH - DRUGS**

Enter a name for your search:  (20 characters max.)

Choose a folder:

### 步骤 3

输入您的检索名称并选择一个文件夹进行保存

例

name of the search: lung tumor

folder: Project1/Searches

完成后点击保存

**SAVE FORM SEARCH - DRUGS**

Do you want to set an email alert for this Saved Search?  Yes  No

Enter your email address:

Include colleagues:

### 步骤 4 设置电子邮件跟踪

Yes : 您可以设置跟踪

No : 只是保存检索

...然后点击 Next

**SAVE FORM SEARCH - DRUGS**

Email alert for 'lung tumor' (number: 6564021)

( this option only available for Drugs)

Optionally restrict to (you can select more than one)

- Development Status Updated
- Chemical Structure Added/Updated
- Reference Added
- Literature Evaluation Added
- Indexing Updated
- Licensing Information Updated
- Editorial Amendments

### 步骤 5

选择接受跟踪服务时您需要的更新/新增信息

例

如果您需要了解最新发展状况：当发展状况更新时，跟踪服务将会自动发送给您。

(\*注意当您选择了任意一个选择框，跟踪系统只对老信息基础上有所更新的内容进行通知，而对新增加的信息不做通知。

如果您没有选择任何一个选择框，则无论是对更新还是新增加的信息都会进行通知。)

点击 Next

**SAVE FORM SEARCH - DRUGS**

Update my saved search

Daily  Weekly  4-Weekly

Notify me if zero results


### 步骤 6 设置跟踪频率

提供选项：

每天，每周，每 4 周

当只有 0 个结果时，选择您是否需要提示信息

点击 Save



步骤 7  
完成跟踪服务的设置




步骤 8  
修改跟踪服务的设置

若要修改或确认您的跟踪服务，请到文件夹进行操作

电子邮件跟踪服务将会提交如下信息：

**From:** Thomson Pharma by email [mailto:alerts@thomson-pharma.com]  
**Sent:** Thursday, December 07, 2006 5:12 PM  
**To:** Inada, Mami (TS - Asia)  
**Subject:** Saved Search Alert 'lung cancer'



列出与您的检索相匹配的报告。  
 列表中显示报告数量。  
 若要查看检索结果，点击“click here”。

只要您登录 Thomson Pharma，检索结果就会显示出来。  
 点击药物名称可以看到某种药物的报告。

**Number of Reports**  
Drug 7 DR

**Display by** [?] Help  
Summary

**Sort by** [?] Help  
Date  
Ascending OR  
Descending order

**Rank by** [?] Help  
Select

**Go to Form Search**

**Search Strategy**  
You searched for: **My Form Search, Drugs:** "egfr family tyrosine kinase receptor inhibitor"+ [Action] AND "lung tumor"+ [Therapy Area] AND ("us" [Country] OR "japan" [Country]) AND restricted to update date, latest 2 weeks

**Process results**  
Print  
Export  
Save

**Summary**

**Select all** [Show Checked](#)

**cetuximab** DR  
Updated on 29 August 2007. Originator: ImClone Systems Inc . Highest Dev Status: Launched.

**EGF vaccine (cancer), CIMAB/ Micromet/Biocon/Bioven** DR  
Updated on 29 August 2007. Originator: The Center of Molecular Immunology . Highest Dev Status: Phase 3 Clinical.

**erlotinib** DR  
Updated on 21 August 2007. Originator: OSI Pharmaceuticals Inc . Highest Dev Status: Launched.

以下信息供您参考：

① 药物报告由于下列“更新原因”而被跟踪

**Drug Report**

OVERVIEW DEVELOPMENT STATUS BIOLOGY CHEMISTRY STRATEGIC PROFILE PATENTS GENERIC COMPETITION MESSAGE MAPPING BIBLIOGRAPHY

SUMMARY DRUG NAME

**SUMMARY**

**Drug name**

**Company**

**Highest dev statu**

**Therapy areas**

**Actions**

**Technologies**

**Target** Nicotinic ACh receptor alpha 4 subunit; Nicotinic ACh receptor beta 2 subunit

**EphMRA Code** N6D

**Update date** 11 June 2008

**Reason for update** Indexing Updated, One or More Development Status Entries Have Been Updated, 1 Reference Added [915122]

更新原因如下

1. 最新研发状态信息
2. 化学结构的添加/更新
3. 参考书目的添加
4. 文献评价的添加
5. 最新治疗领域/作用机制/技术类型
6. 最新许可信息
7. 编辑上的更正

② 下面介绍在药物报告里如何找到“更新原因”

## 1. 最新研发状态信息

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
DEVELOPMENT STATUS DEVELOPMENT STATUS HISTORY THERAPEUTIC USE SCIENTIFIC DATA AND CLINICAL SECTION BIBLIOGRAPHY								

### DEVELOPMENT STATUS i

#### Detailed Status for [AstraZeneca plc](#)

Therapy Area	Country	Status	Reference	Date
Alzheimers disease	Canada	Phase 2 Clinical	<a href="#">815034</a>	23 July 2007
Alzheimers disease	Europe	Phase 2 Clinical	<a href="#">815034</a>	23 July 2007
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	<a href="#">915122</a>	10 June 2008
Cognitive disorder	Canada	Phase 2 Clinical	<a href="#">824725</a>	23 August 2007
Cognitive disorder	US	Phase 2 Clinical	<a href="#">642785</a>	28 December 2005

#### Detailed Status for [Targacept Inc](#)

Therapy Area	Country	Status	Reference	Date
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	<a href="#">915122</a>	10 June 2008


## 2. 化学结构的添加/更新

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
CHEMISTRY CAS RN SCIENTIFIC DATA / CHEMISTRYSECTION BIBLIOGRAPHY								

### CHEMISTRY i

#### Selected compound

Confidence level: 1



[View Mol File](#)

[CJ-13-610](#)

## 3 参考书目的添加

◇参考书目列表（显示了所有的参考书目，您可以快速浏览标题，来源，出版日期）

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
BIBLIOGRAPHY								

### BIBLIOGRAPHY i

Total linked references : 122 [\(Full results list\)](#) First 20 shown. [View all](#)

[915122](#) Targacept and AstraZeneca begin phase II trial of AZD-3480  
Targacept Inc  
Press Release , 2008:June 10 , *Article type: Commercial*

[214236](#) NC100669559: Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects  
www.clinicaltrials.gov , 2008 , *Article type: Commercial*

您可以确认每一个列表的参考书目如何被用于药物报告。

◇概要信息（它显示了关于药物发展的一般概要）

#### OVERVIEW ⓘ

**Targacept** (formerly a subsidiary of [RJ Reynolds](#)) and licensee, [AstraZeneca](#), is developing ispronicline (TC-1734, AZD-3480; structure shown), the lead in a series of nicotinic acetylcholine (nACh) agonists, as a potential oral treatment for Alzheimers disease (AD), schizophrenia-associated cognitive deficits and cognitive impairment including mild cognitive impairment (MCI), age-associated memory impairment (AAMI), attention deficit hyperactivity disorder (ADHD) and other dementias [ [512600](#) ], [ [545766](#) ], [ [642785](#) ], [ [762824](#) ], [ [915122](#) ]. Phase II trials in memory and cognitive disorders in elderly people had been initiated by November 2003 [ [512600](#) ]; in December 2006, following completion of safety and characterization studies, AstraZeneca decided to continue development [ [753585](#) ], [ [762817](#) ]. In July 2007, AstraZeneca began a phase IIb trial for mild-to-moderate AD. At that time, the company expected to begin a phase IIb trial for schizophrenia-associated cognitive deficits in August 2007 [ [815034](#) ]; the trial began in August 2007 [ [824725](#) ]. A phase II ADHD trial was initiated in June 2008. At that time, the phase II trials for AD and schizophrenia-associated cognitive deficits were expected to be completed in the second half of 2008 [ [915122](#) ].

◇发展状况列表

（您可以在表格中看到药物的发展状况，以每一个公司、国家和治疗领域的形式显示。）

#### DEVELOPMENT STATUS ⓘ

Detailed Status for <a href="#">AstraZeneca plc</a>				
Therapy Area	Country	Status	Reference	Date
Alzheimers disease	Canada	Phase 2 Clinical	<a href="#">815034</a>	23 July 2007
Alzheimers disease	Europe	Phase 2 Clinical	<a href="#">815034</a>	23 July 2007
Attention deficit hyperactivity disorder	US	Phase 2 Clinical	<a href="#">915122</a>	10 June 2008
Cognitive disorder	Canada	Phase 2 Clinical	<a href="#">824725</a>	23 August 2007
Cognitive disorder	US	Phase 2 Clinical	<a href="#">642785</a>	28 December 2005

如果更新原因是“参考书目的添加”，同时也会提供参考书目的文献评价更新。

#### 4. 文献评价的添加

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
LITERATURE EVALUATION DRUGDEX EVALUATIONS SCIENTIFIC DATA / BIOLOGY AND METABOLISM SECTIONS BIBLIOGRAPHY								

#### LITERATURE EVALUATION ⓘ

Hugo Geerts, In , Philadelphia, USA

Submission date: 27 August 2005

Publication date: 10 December 2006

##### Introduction

With the observation that a nicotinic acetylcholine (ACh) receptor (nAChR) deficit occurs in neurodegenerative conditions, such as Alzheimer's disease, and in psychiatric conditions, such as schizophrenia, there came a considerable interest in developing nicotinic receptor modulators with a less addictive and toxic profile than nicotine [ [624142](#) ], [ [624143](#) ]. Although different nAChR

#### 5. 最新治疗领域/作用机制/技术类型

## Drug Report

OVERVIEW	DEVELOPMENT STATUS	BIOLOGY	CHEMISTRY	STRATEGIC PROFILE	PATENTS	GENERIC COMPETITION	MESSAGE MAPPING	BIBLIOGRAPHY
SUMMARY	DRUG NAME	BREAKING NEWS	OVERVIEW	DEALS				

### SUMMARY

<b>Drug name</b>	ispronicline
<b>Company</b>	Targacept Inc
<b>Highest dev status</b>	Phase 2 Clinical
<b>Therapy areas</b>	Alzheimers disease; Attention deficit hyperactivity disorder; Cognitive disorder
<b>Actions</b>	Neuroprotectant; Nicotinic ACh receptor alpha 4 subunit modulator; Nicotinic ACh receptor beta 2 subunit modulator; Nicotinic acetylcholine receptor agonist; Nootropic agent; Psychomodulator
<b>Technologies</b>	Oral formulation
<b>Target</b>	<a href="#">Nicotinic ACh receptor</a> ; <a href="#">Nicotinic ACh receptor alpha 4 subunit</a> ; <a href="#">Nicotinic ACh receptor beta 2 subunit</a>
<b>EphMRA Code</b>	N6D
<b>Update date</b>	11 June 2008
<b>Reason for update</b>	Indexing Updated,One or More Development Status Entries Have Been Updated,1 Reference Added [915122]

## 6. 最新许可信息

### ◇概要列表

#### DEALS i

<b>Summary</b>	<a href="#">[Deal Report]</a>
<b>Primary company</b>	<a href="#">Targacept Inc</a>
<b>Partnering company</b>	<a href="#">AstraZeneca plc</a>
<b>Deal Type</b>	Drug - Development/Commercialization License
<b>Start date</b>	28 December 2005

#### Overview

In December 2005, [AstraZeneca](#) and [Targacept](#) entered into an exclusive, global research and license agreement for the development and commercialization of [TC-1734](#), to treat Alzheimer's disease (AD), cognitive deficits in schizophrenia and other cognitive disorders [642914], [642785]. In February 2006, Targacept received an upfront payment from Astrazeneca [648681]. In December 2006, AstraZeneca paid developmental milestone payment to Targacept [753585]. In November 2007, [AstraZeneca](#) acquired an option for an exclusive license to Targacept's [TC-5619](#) [847728].

## 7. 编辑上的更新

这种更新的常见例子是会议或其他消息来源的附加数据，但是并不属于最新研发状态信息列表或最新标定指数。目前尚无法显示这些更新出现在何处。